In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Podsumowanie

Unmodified and hyperphosphorylated tau proteins were used in two in vitro aggregation assays to reveal the hyperphosphorylation-dependent fast aggregation kinetics. These assays pave the way for future screens for compounds that can modulate the propensity of hyperphosphorylated tau to form fibrils that underlie the progression of Alzheimer’s disease.

Streszczenie

Alzheimer's disease is one of a large group of neurodegenerative disorders known as tauopathies that are manifested by the neuronal deposits of hyperphosphorylated tau protein in the form of neurofibrillary tangles (NFTs). The density of NFT correlates well with cognitive impairment and other neurodegenerative symptoms, thus prompting the endeavor of developing tau aggregation-based therapeutics. Thus far, however, tau aggregation assays use recombinant or synthetic tau that is devoid of the pathology-related phosphorylation marks. Here we describe two assays using recombinant, hyperphosphorylated tau as the subject. These assays can be scaled up for high-throughput screens for compounds that can modulate the kinetics or stability of hyperphosphorylated tau aggregates. Novel therapeutics for Alzheimer's disease and other tauopathies can potentially be discovered using hyperphosphorylated tau isoforms.

Wprowadzenie

Alzheimer’s disease (AD) is one of a large collection of neurodegenerative disorders known as tauopathies. The quintessential pathology underlying tauopathy is the neurofibrillary tangles, NFTs, in neurons, astrocytes and microglia ^1-4. The NFT density correlates with cognitive impairment ^3,5 and neuron loss ⁶. NFT contains primarily hyperphosphorylated tau protein (referred to as “p-tau” henceforth) that forms straight or paired helical filaments (PHF) ^7,8. Tau is a microtubule associated protein thought to facilitate axonal transport that is essential for neuronal signaling and trafficking ^9,10. Each tau molecule contains 2 to 3 phosphates in normal brain, but the phosphoryl content increases by several folds in tauopathy patients ¹¹. Multiple kinases are likely to contribute to tau hyperphosphorylation including GSK3β (glycogen synthase kinase 3β) and CDK5 (cyclin-dependent kinase 5) ^12,13, but the direct trigger for the pathological phosphorylation remains elusive ¹⁴. Abnormal phosphorylation in or near the microtubule-binding motifs dissociates tau from the microtubule ¹⁵, and causes tau mis-localization to the somatodendritic compartment, where p-tau oligomerizes into straight or paired helical filaments that can eventually polymerize into NFT inclusions. The close tie between tau hyperphosphorylation, NFT formation, and neurodegeneration led to a prevalent hypothesis that p-tau tangles elicit apoptotic and other cytotoxic responses, and thus is the underlying cause for tauopathy neurodegeneration ^16,17. Drug screens and early clinical tests based on this premise have been launched ¹⁸. However, this hypothesis faces challenges ^19,20. For example, SantaCruz et al. showed that cognitive functions of transgenic mice can be improved by suppressing the expression of a mutant human tau, even though NFTs continued to form from existing tau molecules ²¹. In a Drosophila model, NFT was shown to sequester the toxic cytosolic tau to protect the underlying neuron cells ^22,23. Clearly, the pathogenesis role of NFT, if any, will greatly impact the direction of tauopathy therapeutics development.

In high concentrations, recombinant or normal brain tau protein spontaneously but slowly polymerizes into a PHF-like structure in vitro, as indicated by the binding of several β-sheet preferred fluorescent dyes, electron microscopy, and light scattering spectroscopy ^24-27. Adding heparin or arachidonic acid, an abundant fatty acid in human brain, drastically accelerates PHF formation in tau isoform- and inducer concentration-dependent manners ^28-32. Intriguingly, hyperphosphorylated tau purified from AD brains or prepared by exhaustive in vitro phosphorylation reactions aggregates faster and more efficiently ^26,33-35. These results are in excellent agreement with the pathological roles of p-tau. An in vitro system based on the aggregation of p-tau may thus serve as a powerful tool for AD drug screening.

Given the close association between tau aggregation and the progressive neurodegeneration of AD, as well as the recent failure in drug development targeting the Aβ plaque, another key histological marker of AD ^36-38, the interest in discovering drugs that control tau aggregation is rising. Indeed, several groups have already begun drug screens at different throughput, using in vitro tau aggregation reactions as the primary assay. A number of chemicals were found to exhibit inhibitory or reversal activities on tau aggregation in vitro ^39-42. However, all current tau aggregation regulator screens use unmodified tau that misses the key pathological mark of phosphorylation, raising a concern for the specificity and efficacy of using these compounds in AD treatment.

One of the major hurdles of developing aggregation assays for biochemical characterization and AD drug screening is the production of sufficient quantities of the pathophysiologically relevant hyperphosphorylated tau protein. Using the Zippers-Assisted Catalysis system in which the 1N4R isoform of tau and the GSK-3β kinase are co-expressed in E. coli as leucine zipper fusion proteins, we have overcome this challenge (Sui et al., submitted; see Figure 1 for the final products of tau and p-tau; also see ⁴³ for preliminary mass spectrometry characterization of p-tau). From a panel of nine antibodies specific for different phosphorylation sites of tau, positive signals were seen in eight positions (data not shown). Below, we describe protocols and instrumentations that can differentiate the aggregation kinetic differences between unmodified tau and p-tau species. These assays were modified from published protocols that measured the increase of fluorescence of thioflavin T (ThT) or thioflavin S (ThS) upon amyloid (tau aggregates) binding ²⁶. In the first “terminal”, no-dye approach, aggregation reactions are assembled and incubated in the absence of the amyloid dye. At different time points, an aliquot of each reaction is removed and mixed with equal volume of the ThT-containing buffer to stop aggregation and allow ThT to bind tau aggregates. Fluorescence is measured by an IAP FluoroMax-2 fluorometer. In the second “with-dye” continual monitoring assay, ThT or ThS is included in the aggregation reactions. Fluorescence can be measured continuously throughout the entire experiment manually or using a multi-plate reader. In addition, we describe an assay that uses a near-physiological concentration of tau and p-tau for aggregation in the continual measurement mode. The effect of phosphorylation remains readily detectable. Below, we will describe step-by-step operation procedures, and show representative results of these assays. Discussion of some of the pros and cons of each approach, as well as potential drug screening applications will follow.

At a high concentration, tau aggregates into amyloid-like structures spontaneously. However, in the laboratory, tau fibrillization is typically accelerated by such inducers as heparin (average molecular weight, 6,000 g/mol) and arachidonic acid. Examples shown herein include 30 µM heparin. The formation of tau amyloid aggregates is monitored by the fluorescence resulting from amyloid binding by thioflavin T (ThT) or thioflavin S (ThS). Upon binding to tau aggregates, ThT exhibits a red shift in fluorescence (excitation: 450 nm; peak emission: 485 nm). ThS, on the other hand, has weak emission at 510 nm (excitation at 450 nm) before amyloid binding, but this fluorescence increases significantly in the presence of an amyloid protein such as the aggregated tau ⁴⁴. Both dyes work well in detecting tau and p-tau aggregation. Because of the strong and relatively broad emission peak of ThT (see Figure 2), there is only 30% reduction in the fluorescence unit at 510 nm. For convenience, we use the same combination of excitation/emission wavelengths (i.e., 450 nm/510 nm) to monitor tau aggregation when using either dye.

Tau aggregation can be done in the presence or absence of the dye, depending on the purpose of the assay and the availability of tau protein. Both modes of reactions are shown below. In addition, we demonstrate the operation of two different instruments – a single-sample fluorometer (ISA-SPEX FluoroMax-2) and a multi-plate reader (SpectraMax M2). Readers should be able to adapt these protocols to suit their specific needs and instrument availability.

Protokół

1. Preparation of Reagents

1. Prepare aggregation buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA). Store at RT, stable for months. Supplement 1 mM dithiothreitol (DTT) before use.
   NOTE: a HEPES-based buffer (10 mM HEPES, pH 7.5, 0.1 mM EDTA, 5 mM DTT) also produces similar results in tau aggregation.
2. Prepare thioflavin T or thioflavin S stock solution (3 mM, dissolved in aggregation buffer), and filter by 0.22 μm sterile filter unit. Store at –20 °C in a tube covered by aluminum foil, stable for months.
3. Prepare heparin stock solution (300 μM, dissolved in aggregation buffer). Store at –20 °C, stable for months.
4. Prepare dithiothreitol (DTT) stock (1 M, dissolved in water). Aliquot into 1.5 ml tubes. Store at –20 °C. Before aggregation assays, thaw the 1 M solution at RT. From this 1,000x stock, prepare an aliquot of 100 mM working stock with deionized water. Leave on ice until ready.
5. Remove tau from –80 °C freezer. Thaw on ice. Adjust tau to predetermined concentration with the aggregation buffer. Spin in a microcentrifuge at 20,800 x g for 10 min at 4 °C to remove pre-formed large aggregates. This pre-spinning step increases consistency in the subsequent fluorescence measurement of each batch of the protein prep. Transfer the supernatant to another tube; leave on ice until ready to assemble the aggregation reaction.

2. No-dye, Terminal Assay

NOTE: The aggregation reaction of this assay is done in the absence of the fluorescent dye. After mixing all components, the reaction is allowed to proceed to pre-determined time points. Aliquots are then taken out of the aggregation reaction and mixed with ThT or ThS for amyloid binding before fluorescence reading. The initial volume of the aggregation reaction depends on the number of time points needed. This approach may require a large amount of tau protein, but is fast, straightforward, and can be done in a fluorometer or a multi-well plate reader (see Discussion). Below is the step-by-step operation, using the ISA SPEX FluoroMax-2 compact spectrofluorometer for fluorescence quantification.

1. Set up the aggregation mixture in 1.5 ml Eppendorf tubes as in Table 1. Each column represents the ingredients needed for a 100 μl reaction, which is enough for one time-point measurement. Adjust the amount for the entire aggregation mix based on the time points needed for the particular experiment. Add additional 10% of each component to give room for pipetting error. The typical reaction containing heparin shown here can be replaced by arachidonic acid or aggregation buffer. Add DTT to 1 mM to the reaction mixture. If the entire reaction lasts more than one day, supplement fresh DTT everyday (1 mM) to ensure a reducing environment.
2. Invert the tube a few times to mix. Place each reaction in a 37 °C incubator or water bath. Agitation is not needed for tau aggregation.
3. Before measuring the fluorescence, turn on the spectrofluorometer (lamp first, then computer).
   NOTE: The xenon arc lamp that can be used right away. However, for best results allow the machine to warm up for about 10 min before reading fluorescence.
4. Start the software on the computer.
   1. Choose Real Time Display mode in Instrument Control Center, set excitation wavelength to 450 nm (slit to 2 nm) and emission wavelength to 510 nm (slit to 5 nm). Close Real Time Display mode window to return to the Instrument Control Center.
   2. Choose Constant Wavelength Analysis, press Add>> key in the upper frame to add wavelengths sets. Set acquisition parameters of Standard Error to 1 and Maximum Trials to 3, then click Add. Click Go! to open the Data Display window.
   3. In the Data Display window, click Start Acq to open the New Sample dialog box. Choose “unknown” for sample type.
5. To every 100 μl aggregation mixture, add 98 µl aggregation buffer and 2 µl 3 mM thioflavin T. Pipet several times to mix.
6. Transfer the entire mixture to a cuvette (FCA3, exterior dimension, w x l x h = 12.5 mm x 12.5 mm x 45 mm). Place the cuvette in the sample holder in the sample-compartment and close the lid. Click Run to collect the fluorescence data. Record the data.
7. Remove the cuvette and decant the solution. Rinse the cuvette by distilled water 3 times. Dry by blowing air in and outside the cuvette.

3. With-dye, Continual Mode Assay on a SpectraMax M2 Plate Reader

NOTE: This assay differs from the previous one in that the fluorescent dye ThT or ThS is included in the aggregation reaction. This allows continuous measurement of the same set of reactions. Because of the repetitive use of the reaction, this method is better done with an automatic multi-well plate reader (as shown below the operation of SpectraMax M2). A regular fluorometer also works but the frequency of measurement of fast aggregation reactions is somewhat limited, due to the manual nature of the operation.

1. Set up the aggregation mix in a 96-well plate (96-well black solid plate, well-volume 360 μl, flat bottom) as in Table 2. Each column represents the ingredients needed for a 200 μl reaction, which is enough for one time-point measurement. Mix well by pipetting several times. Supplement fresh 1mM DTT every day throughout the course of experiments.
2. Incubate the 96-well plate at 37 °C.
3. At each time point before fluorescence measurement, turn on the multi-mode microplate reader and the computer. Allow sufficient time for the machine to stabilize, about 10 min.
4. Start the software on the computer. Set temperature to 37 °C and choose Fluorescence Intensity (FI-Top Read) mode, set excitation wavelength at 450 nm and emission wavelength at 510 nm.
5. Insert the 96-well plate into the drawer and press the READ key to start measurement.
6. After reading, remove the plate and return it back to the 37 °C incubator. Copy the data and paste into an Excel spreadsheet for data analysis and plotting.

4. With-dye, Continual Mode Assay on an Compact Spectrofluorometer

1. Set up the aggregation mixture in 1.5 ml Eppendorf tubes as in Table 3. Each column represents the ingredients needed for a 200 μl reaction, which is enough for one time-point measurement.
2. Invert the tube a few times to mix.
3. Turn on the spectrofluorometer and set the software as in steps 2.3 and 2.4.
4. Transfer the entire mixture to a cuvette. Place the cuvette in the sample holder in the sample-compartment and close the lid. Click Run to collect the fluorescence data. Record the data.
5. Continue reading at appropriate intervals by clicking Run and recording the data. If the aggregation is to be monitored at a high frequency (e.g., every 30 or 60 sec), leave the reaction in the cuvette and in the machine until either the measurement is finished, or when there is sufficient time to swap reactions or cuvettes.
6. Remove the cuvette and decant the solution. Rinse the cuvette by distilled water 3 times. Dry by blowing air in and outside the cuvette.

Wyniki

Using recombinant tau and p-tau (Figure 1), we established two different protocols to compare the kinetics of aggregation of tau and p-tau, taking advantage of the strong fluorescence emission of ThT and ThS upon binding to amyloidal protein aggregates, including tau and p-tau (Figure 2). With or without the fluorescent dye in the aggregation reaction, we observed consistent enhancement of tau aggregation by hyperphosphorylation (Figures 3–5). This stimulation is i...

Dyskusje

This protocol demonstrates different assay conditions and instruments that detect the phosphorylation-dependent fast tau aggregation kinetics. In the terminal assay, the fluorescence dye ThT is added to a portion of the reaction removed from the master mix at each time point. Amyloid binding-induced fluorescence is then measured ²⁶. In the second, with-dye mode, tau aggregation is carried out in the presence of ThT or ThS, rendering this type of reaction suitable for real-time automatic assessment of the growt...

Materiały

Name	Company	Catalog Number	Comments
Trizma base	Sigma	T1503
NaCl	Macron Fine Chemicals	MAL-7581-06
Ethylenediaminetetraacetic Acid (EDTA)	Invitrogen	15576-028
Thioflavin T	Sigma	T3516	Stored in dark
Thioflavin S	Sigma	T1892	Stored in dark
heparin	Sigma	H3393
DL-Dithiothreitol (DTT)	Sigma	D9779	Stored at 4 °C
96-well plate	Corning	3917
ISA SPEX FluoroMax-2	Horiba
SpectraMax M2 Multi-Mode Microlate Reader	Molecular Devices
Mouse Anti-Tau Monoclonal Antibody	R&D Systems	MAB3494	Stored at –80 °C